Pharmafile Logo

FDA approved

- PMLiVE

Teva and Samsung Bioepis to commercialise two FDA-approved biosimilars in the US

Teva will get US commercialisation rights for Eticovo upon close and infliximab in Q3 2027

- PMLiVE

Fresenius and WuXi Biologics announce agreement to expand biosimilars pipeline

The agreement gives Fresenius exclusive option rights for up to 37 potential first-to-market biosimilar candidates

- PMLiVE

Sandoz announces collaboration agreement with Shanghai Henlius Biotech

The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company

- PMLiVE

Sandoz partners with Samsung Bioepis to develop up to five biosimilars

The agreement will expand the pipeline and builds on an existing partnership

EU flag

EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

- PMLiVE

FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma

The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis

EU flag

EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases

The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

EU flag

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

- PMLiVE

FDA approves Samsung Bioepis’ Soliris biosimilar Epysqli for rare blood disorders

Epysqli has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

- PMLiVE

FDA approves Samsung Bioepis’ Stelara biosimilar Pyzchiva for inflammatory conditions

The drug has been authorised to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links